Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2a Study to Determine the Safety of Intratumoral Infusion of Large Surface Area Microparticle (LSAM)-Cisplatin in Participants With Diffuse Midline Glioma (DMG), Including Diffuse Intrinsic Pontine Glioma (DIPG)

NCT07767110 is registered in ClinicalTrials.gov with NanOlogy, LLC as lead sponsor.

NCT NCT07767110
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07767110 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2a Study to Determine the Safety of Intratumoral Infusion of Large Surface Area Microparticle (LSAM)-Cisplatin in Participants With Diffuse Midline Glioma (DMG), Including Diffuse Intrinsic Pontine Glioma (DIPG)
Lead sponsor
NanOlogy, LLC
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
December 31, 2026
Completion date
December 31, 2029
Enrollment
20 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse intrinsic pontine glioma (dipg), diffuse midline glioma (dmg), diffuse midline glioma or diffuse intrinsic pontine glioma